Education
About Us
Working with TipRanks
Follow Us
Palatin (PTN)
:PTN
PTN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.16 - $2.48
Previous CloseN/A
Volume114.38K
Average Volume (3M)N/A
Market Cap
$6.13M
Enterprise Value-$410.06K
Total Cash (Recent Filing)$3.42M
Total Debt (Recent Filing)$357.74K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
May 20, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding28,148,846
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.30
Price to Sales (P/S)0.00
P/FCF Ratio-0.10
Enterprise Value/Market Cap-0.07
Enterprise Value/Revenue-0.03
Enterprise Value/Gross Profit-2.30
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.00Price Target Upside6900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Palatin Technologies News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe completion of the Phase 2 BMT-801 clinical trial is a significant milestone for Palatin as it focuses on the obesity space, which is seen as a key driver of the company's long-term success.
Strategic FocusPalatin's strategic focus has shifted primarily to its obesity program, which management views as the primary driver of long-term success.
Bears Say
Clinical Trial RisksFactors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.
Financial NeedsThe company is in talks with sources to address its future operating cash needs.
Options Prices
Currently, No data available
---
Ownership Overview
2.20% Insiders
1.93% Mutual Funds
7.24% Other Institutional Investors
87.15% Public Companies and
Individual Investors
PTN FAQ
What was Palatin’s price range in the past 12 months?
Palatin lowest stock price was $0.16 and its highest was $2.48 in the past 12 months.
What is Palatin’s market cap?
Palatin’s market cap is $6.13M.
When is Palatin’s upcoming earnings report date?
Palatin’s upcoming earnings report date is May 20, 2025 which is 64 days ago.
How were Palatin’s earnings last quarter?
Currently, no data Available
Is Palatin overvalued?
According to Wall Street analysts Palatin’s price is currently Undervalued.
Does Palatin pay dividends?
Palatin does not currently pay dividends.
What is Palatin’s EPS estimate?
Palatin’s EPS estimate is -0.17.
How many shares outstanding does Palatin have?
Palatin has 28,148,846 shares outstanding.
What happened to Palatin’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palatin?
Currently, no hedge funds are holding shares in PTN
Company Description
Palatin
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
PTN Stock 12 Month Forecast
Average Price Target
$7.00
▲(6900.00%Upside)